Human Papillomavirus Infection as a Prognostic Factor in Oropharyngeal Squamous Cell Carcinoma Patients Treated in a Prospective Phase II Clinical Trial

Por Jo, Solomon, Juhasz, Agnes, Zhang, Keqiang, Ruel, Christopher, Wilczynski, Sharon P., Yen, Yun, Shibata, Stephen
Publicado em 2009

Phase II study of Belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

Por Ramalingam, Suresh S., Belani, Chandra P., Ruel, Christopher, Frankel, Paul, Gitlitz, Barbara, Koczywas, Marianna, Espinoza-Delgado, Igor, Gandara, David
Publicado em 2009

A Phase 2 Study of Belinostat (PXD101) in Patients with Relapsed or Refractory Acute Myloid Leukemia or Patients Over 60 with Newly-Diagnosed Acute Myloid Leukemia: A California Ca...

Por Kirschbaum, Mark H., Foon, Kenneth A., Frankel, Paul, Ruel, Christopher, Pulone, Bernadette, Tuscano, Joseph M., Newman, Edward M.
Publicado em 2014

Phase II Study of Aflibercept (VEGF-Trap) in Patients with Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

Por Twardowski, Przemyslaw, Stadler, Walter M, Frankel, Paul, Lara, Primo N, Ruel, Christopher, Chatta, Gurkamal, Heath, Elisabeth, Quinn, David I, Gandara, David R
Publicado em 2010

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

Por Tarhini, Ahmad A., Frankel, Paul, Margolin, Kim A., Christensen, Scott, Ruel, Christopher, Shipe-Spotloe, Janice, Gandara, David R, Chen, Alice, Kirkwood, John M.
Publicado em 2011

Pharmcodynamics (PD) and Pharmacokinetics (PK) of E7389 (Eribulin, Halichondrin B Analog) During a Phase I Trial in Patients with Advanced Solid Tumors: A California Cancer Consort...

Por Morgan, Robert J., Synold, Timothy W., Longmate, Jeffrey A., Quinn, David I, Gandara, David, Lenz, Heinz-Josef, Ruel, Christopher, Xi, Bixin, Lewis, Michael D., Colevas, A. Dimitrios, Doroshow, James, Newman, Edward M.
Publicado no Cancer Chemother Pharmacol (2015)

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fuoro-2′-deoxycytidine, administered with tetrahydrouridine

Por Newman, Edward M., Morgan, Robert J., Kummar, Shivaani, Beumer, Jan H., Blanchard, M. Suzette, Ruel, Christopher, El-Khoueiry, Anthony B., Carroll, Mary I., Hou, Jessie M., Li, Chun, Lenz, Heinz J., Eiseman, Julie L., Doroshow, James H.
Publicado no Cancer Chemother Pharmacol (2015)